Given as the EZH2 mutation remodels the FL tumor cells’ interactions with the tumor microenvironment [77], it is intriguing to speculate that combinational approaches of tazemetostat with other targeted therapies may be synergistic. The gene discussed is EZH2; the disease is neoplasm.